Who are Antizol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Depakene, Divalproex, Antizol, Epilim, Cyanokit, Acetadote.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fomepizole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Antizol — Competitive Intelligence Brief

Antizol (FOMEPIZOLE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidote [EPC]. Area: Metabolic.

marketed Antidote [EPC] Alcohol dehydrogenase Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Antizol (FOMEPIZOLE) — Par Pharm Inc. Antizol works by competitively inhibiting the enzyme alcohol dehydrogenase, which is responsible for converting toxic alcohols into their more toxic metabolites.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Antizol TARGET	FOMEPIZOLE	Par Pharm Inc	marketed	Antidote [EPC]	Alcohol dehydrogenase	1997-01-01
Depakene	valproic acid	Generic (originally Abbott/AbbVie)	marketed	Anti-epileptic Agent [EPC]	Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2	1978-02-28
Divalproex	Divalproex	University of Chicago	marketed		Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2
Antizol	Antizol	Amgen	marketed		Alcohol dehydrogenase, Alcohol dehydrogenase
Epilim	sodium valproate	Sanofi	marketed		Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2
Cyanokit	HYDROXOCOBALAMIN	Btg Intl	marketed	Antidote		1978-01-01
Acetadote	Acetylcysteine	Bristol-Myers Squibb	marketed	Antidote	Glutathione levels; reactive metabolite of acetaminophen	1963-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-05-21 — Acetadote · 8148356 · Formulation · US
2031-07-21 — Acetadote · 9327028 · Method of Use · US
2032-04-06 — Acetadote · 8722738 · Method of Use · US
2032-05-08 — Acetadote · 8747894 · Formulation · US
2032-05-08 — Acetadote · 9561204 · Method of Use · US
2032-05-08 — Acetadote · 9427421 · Formulation · US

Sponsor landscape (Antidote [EPC] class)

New York State Institute for Basic Research · 1 drug in this class
Par Pharm Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Antizol — Competitive Intelligence Brief. https://druglandscape.com/ci/fomepizole. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab